EmendoBio is involved in developing CRISPR-based gene editing technologies to address complex genetic diseases, focusing on optimizing nucleases and guide-RNAs for effective disease-specific solutions.
peer of
competitor of
Metrics
marketPRIVATE
msh_idCOM:EMENDOBIO
localeus
websitehttps://www.emendobio.com/
source_ref710bdcbc-c8a6-4d73-8798-b4d7070f68e8
products_or_servicesGene editing technology platform that provides customized nucleases and guide-RNAs for targeting genetic diseases.
United States